Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ribociclib - Novartis Oncology

Drug Profile

Ribociclib - Novartis Oncology

Alternative Names: Kisqali; LEE-011; LEE-011A

Latest Information Update: 25 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics
  • Developer Array BioPharma; Cedars-Sinai Medical Center; Cincinnati Children's Hospital Medical Center; Cliniques Universitaires Saint Luc; Georgetown University; Gynecologic Oncology Group; Hadassah Medical Organization; Mayo Clinic; National Cancer Institute (USA); Novartis; Novartis Oncology; Roswell Park Cancer Institute; St Josephs Hospital and Medical Center; Thomas Jefferson University; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center; Virginia Mason Research Center
  • Class Amides; Aminopyridines; Antineoplastics; Piperazines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Liposarcoma; Pancreatic cancer
  • Phase I Lymphoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Discontinued Endometrial cancer; Fallopian tube cancer; Glioma; Head and neck cancer; Liver cancer; Malignant melanoma; Meningioma; Neuroblastoma; Neuroendocrine tumours; Prostate cancer; Rhabdoid tumour; Teratoma

Most Recent Events

  • 11 Nov 2019 The Scottish Medicines Consortium recommends Ribociclib for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in Scotland
  • 29 Sep 2019 Updated interim efficacy and adverse events data from a the phase III MONALEESA-3 trial in Breast cancer released by Novartis
  • 30 Jul 2019 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Belgium, Singapore (PO, Capsule) (NCT04000529)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top